FOXM1 and small cell lung carcinoma: Kim et al. [72] has shown that MELK phosphorylates the oncogenic transcription factor Forkhead Box M1 (FOXM1) and that the MELK/FOXM1 complex targets EZH2, which in turn promotes CSC resistance to drugs and radiation[18,61], and that an inhibitor of MELK OTS167 robustly eliminates CSCs from small cell lung cancer (SCLC)[73,74].